Salani R - Search Results

1

Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.

Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM. Barrington DA, et al. Among authors: salani r. Surg Oncol. 2020 Sep;34:40-45. doi: 10.1016/j.suronc.2020.03.001. Epub 2020 Mar 11. Surg Oncol. 2020. PMID: 32891351

2

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD. Bristow RE, et al. Among authors: salani r. Gynecol Oncol. 2007 Sep;106(3):476-81. doi: 10.1016/j.ygyno.2007.05.043. Epub 2007 Aug 3. Gynecol Oncol. 2007. PMID: 17688927

3

Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma.

Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Salani R, et al. Ann Surg Oncol. 2007 Dec;14(12):3552-7. doi: 10.1245/s10434-007-9565-7. Epub 2007 Sep 25. Ann Surg Oncol. 2007. PMID: 17896149

4

Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.

Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Salani R, et al. Gynecol Oncol. 2008 Feb;108(2):271-5. doi: 10.1016/j.ygyno.2007.11.004. Gynecol Oncol. 2008. PMID: 18164380

5

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.

Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O'Malley DM. Hurt JD, et al. Among authors: salani r. Gynecol Oncol. 2009 Dec;115(3):396-400. doi: 10.1016/j.ygyno.2009.08.032. Epub 2009 Oct 4. Gynecol Oncol. 2009. PMID: 19804901

6

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. O'Malley DM, et al. Among authors: salani r. Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18. Gynecol Oncol. 2011. PMID: 21315428

7

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.

Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Salani R, et al. Am J Obstet Gynecol. 2011 Jun;204(6):466-78. doi: 10.1016/j.ajog.2011.03.008. Am J Obstet Gynecol. 2011. PMID: 21752752 Review.

8

The impact of body weight on ovarian cancer outcomes.

Backes FJ, Nagel CI, Bussewitz E, Donner J, Hade E, Salani R. Backes FJ, et al. Among authors: salani r. Int J Gynecol Cancer. 2011 Dec;21(9):1601-5. doi: 10.1097/IGC.0b013e31822d2aa3. Int J Gynecol Cancer. 2011. PMID: 21997171 Free PMC article.

9

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Nagel CI, et al. Among authors: salani r. Gynecol Oncol. 2012 Feb;124(2):221-4. doi: 10.1016/j.ygyno.2011.10.003. Epub 2011 Nov 4. Gynecol Oncol. 2012. PMID: 22055764 Free PMC article.

10

Surgical management of epithelial ovarian cancer.

Salani R, Bristow RE. Salani R, et al. Clin Obstet Gynecol. 2012 Mar;55(1):75-95. doi: 10.1097/GRF.0b013e31824b4629. Clin Obstet Gynecol. 2012. PMID: 22343231 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

152 results

Search Page